1-3 of 3
Anna Purdum, PharmD,MS
Close
Sort by
Journal Articles

The First Retrospective Commercial Claims-Based Analysis of CAR T Treated Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Anna Purdum, PharmD,MS, Jonathan Johnson, Anthony Bonagura, Liliosa Nyamutswa, MPH, Caitlin Elliott, MS, Lincy S. Lal, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31.
https://doi.org/10.1182/blood-2020-134735
Published: 2020
Journal Articles

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Karl M. Kilgore, PhD, Iman Mohammadi, PhD, Amy Schroeder, BPharm, Christie Teigland, PhD, Anna Purdum, PharmD,MS, Gunjan L. Shah, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 793.
https://doi.org/10.1182/blood-2019-124364
Published: 2019
Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 764.
https://doi.org/10.1182/blood-2019-124750
Published: 2019